BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for 4D Molecular Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 4:08 pm Sale | 2026-03-31 | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | BIOTECHNOLOGY VALUE FUND L P | 5,346,519 9.990% | -500,762 (-8.56%) | Filing |
| 2026-02-17 4:12 pm Purchase | 2025-12-31 | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | BIOTECHNOLOGY VALUE FUND L P | 5,847,281 9.990% | 1,214,532 (+26.22%) | Filing |
| 2025-05-15 4:29 pm Sale | 2025-03-31 | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | BIOTECHNOLOGY VALUE FUND L P | 4,632,749 9.990% | -201,548 (-4.17%) | Filing |
| 2025-02-14 4:20 pm Sale | 2024-12-31 | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | BIOTECHNOLOGY VALUE FUND L P | 4,834,297 9.990% | -2,548,345 (-34.52%) | Filing |
| 2024-11-13 4:08 pm Purchase | 2024-09-30 | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | BIOTECHNOLOGY VALUE FUND L P | 7,382,642 14.200% | 3,375,229 (+84.22%) | Filing |
| 2024-02-14 09:56 am Unchanged | 2023-12-31 | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | BIOTECHNOLOGY VALUE FUND L P | 4,007,413 9.400% | 0 (Unchanged) | Filing |
| 2022-06-21 4:53 pm Purchase | 2022-06-16 | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | BIOTECHNOLOGY VALUE FUND L P | 4,007,413 12.400% | 2,001,551 (+99.79%) | Filing |